BrECADD for advanced Hodgkin lymphoma in HIV patients
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new drug combination called BrECADD for people who have both HIV and advanced-stage Hodgkin lymphoma. The goal is to see if it works well while being safe for people living with HIV.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed first diagnosis of classic Hodgkin lymphoma.
- Your lymphoma must be advanced stage (stage IIB with a large chest mass or spread to other organs, or stage III or IV).
- You must have HIV and a CD4 count of at least 150 at the time of registration, or a CD4 count over 250 in the 8 months before your lymphoma diagnosis.
- You must be taking HIV medications (antiretroviral therapy) or willing to start them.
- You must be between 18 and 60 years old.
- You cannot have had any other cancer in the last 5 years, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination drug treatment called BrECADD for people with Hodgkin lymphoma that has certain risk factors or is in a more advanced stage (stage 2B, 3, or 4). It aims to see if this treatment works well and is safe.
This trial tests a newer, lower-dose immunotherapy combination (AVD plus nivolumab) against a standard intensive chemo regimen (BEACOPP) that is adjusted based on PET scan results. It is for people with advanced classical Hodgkin lymphoma that has not been treated before.
This trial tests a combination of three drugs (chidamide, decitabine, and an immunotherapy) for people with classical Hodgkin lymphoma that has come back or not responded to at least two prior treatments. It is for patients who cannot or choose not to have a stem cell transplant.
This trial tests a combination of four drugs (homoharringtonine, a BCL-2 inhibitor, rituximab, and prednisone) for people with diffuse large B-cell lymphoma that has come back or not responded to earlier treatment. It aims to see if this new mix can help when standard therapies have stopped working.
This trial tests a new drug called HCB301, which targets proteins that help cancer hide from the immune system. It is for people with advanced solid tumors or classical Hodgkin lymphoma who have tried other treatments without success.
This trial tests a combination of two oral targeted drugs (chidamide and decitabine) plus an immunotherapy drug (anti-PD-1 antibody) for people with classical Hodgkin lymphoma that has not responded to at least two prior treatments and who cannot or choose not to have a stem cell transplant. The goal is to see if this three-drug combination can shrink tumors and help control the disease.
Hear when a new Hodgkin Lymphoma (Category) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.